KURZROCK R[au] - Search Results

Year	Number of Results
1984	3
1985	3
1986	9
1987	13
1988	13
1989	11
1990	11
1991	25
1992	12
1993	19
1994	9
1995	20
1996	7
1997	13
1998	8
1999	10
2000	6
2001	10
2002	10
2003	10
2004	10
2005	10
2006	11
2007	17
2008	17
2009	26
2010	37
2011	44
2012	50
2013	63
2014	64
2015	76
2016	51
2017	51
2018	49
2019	43
2020	67
2021	49
2022	46
2023	43
2024	62
2025	52
2026	28

1

Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.

Ahmed J, Nishizaki D, Fujiwara Y, DePietro P, Jensen TJ, McFall T, Kato S, Kurzrock R. Ahmed J, et al. Among authors: kurzrock r. ESMO Open. 2026 Jun 9;11(6):107768. doi: 10.1016/j.esmoop.2026.107768. Online ahead of print. ESMO Open. 2026. PMID: 42263481 Free article.

2

GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M, Jensen TJ, Conroy JM, DePietro P, Sicklick JK, Kato S. Moussa P, et al. Among authors: kurzrock r. Mol Cancer Ther. 2026 May 25:OF1-OF11. doi: 10.1158/1535-7163.MCT-25-0713. Online ahead of print. Mol Cancer Ther. 2026. PMID: 42179191

3

Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.

Fountzilas E, Kurzrock R, Nishizaki D, Szabo A, Pabla S, DePietro P, Jensen TJ, Kato S, Tsimberidou AM. Fountzilas E, et al. Among authors: kurzrock r. Immunotargets Ther. 2026 May 4;15:578703. doi: 10.2147/ITT.S578703. eCollection 2026. Immunotargets Ther. 2026. PMID: 42111506 Free PMC article.

4

The case for tumour-agnostic reimbursement of dual immunotherapy.

Subbiah V, Kurzrock R. Subbiah V, et al. Among authors: kurzrock r. Eur J Cancer. 2026 Jun 18;241:116784. doi: 10.1016/j.ejca.2026.116784. Epub 2026 May 5. Eur J Cancer. 2026. PMID: 42106259

5

GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M, Jensen TJ, Conroy JM, DePietro P, Sicklick JK, Kato S. Moussa P, et al. Among authors: kurzrock r. Mol Cancer Ther. 2026 May 5. doi: 10.1158/1535-7163.MCT-25-0713. Online ahead of print. Mol Cancer Ther. 2026. PMID: 42083087

6

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy.

Fujiwara Y, Kato S, Nishizaki D, Miyashita H, Lee S, Jensen TJ, DePietro P, Seager RJ, Ikeda S, Kurzrock R. Fujiwara Y, et al. Among authors: kurzrock r. NPJ Precis Oncol. 2026 Apr 28. doi: 10.1038/s41698-026-01427-9. Online ahead of print. NPJ Precis Oncol. 2026. PMID: 42049950 Free article.

7

Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets.

Murthy D, Seyhan AA, den Hollander P, Lu S, Kuburich NA, Gould C, Karam AA, Sun K, Schupp PG, Safran H, Kurzrock R, El-Deiry W, Mani SA. Murthy D, et al. Among authors: kurzrock r. Mol Aspects Med. 2026 Jun;109:101476. doi: 10.1016/j.mam.2026.101476. Epub 2026 Apr 19. Mol Aspects Med. 2026. PMID: 42008879 Free article. Review.

8

DART (NCI/SWOG S1609): comprehensive final results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.

Patel SP, Othus M, Chae YK, Azenkot T, Alviz C, Threlkel S, Haymaker C, Streicher HZ, Magner CM, Chen HX, Sharon E, Ryan CW, Blanke CD, Kurzrock R. Patel SP, et al. Among authors: kurzrock r. Ann Oncol. 2026 Apr 15:S0923-7534(26)00142-0. doi: 10.1016/j.annonc.2026.04.004. Online ahead of print. Ann Oncol. 2026. PMID: 41997295

9

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results.

Chae YK, Czeskleba J, Patel SP, Mentor A, Robinson W, Jones NL, Rampurwala M, Naing A, Beck JM, Moloney-Lineen C, Chung LI, McLeod CM, Chen HX, Sharon E, Threlkel S, Othus M, Ryan CW, Blanke CD, Kurzrock R. Chae YK, et al. Among authors: kurzrock r. J Gynecol Oncol. 2026 Mar 25. doi: 10.3802/jgo.2026.37.e92. Online ahead of print. J Gynecol Oncol. 2026. PMID: 41995270 Free article.

10

Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.

Low SK, Fujiwara Y, Nishizaki D, Kato S, Kurzrock R. Low SK, et al. Among authors: kurzrock r. J Immunother Precis Oncol. 2026 Apr 14;9(2):36-45. doi: 10.36401/JIPO-25-31. eCollection 2026 Apr. J Immunother Precis Oncol. 2026. PMID: 41994077 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,089 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,089 results

Results by year